Senomyx
This article was originally published in The Tan Sheet
Executive Summary
La Jolla, Calif.-based Senomyx will work with Tokyo-based food and culinary product firm Ajinomoto to develop "specific natural flavor ingredients" over a three-year period, under the terms of a second research and commercialization agreement announced Oct. 11. Additionally, the U.S. Patent & Trademark Office issued Senomyx a patent for human bitter taste receptors shown to be activated by artificial sweeteners saccharin and acesulfame potassium, Senomyx says in a Sept. 26 release. The receptors will be used by the firm to screen for new flavor ingredients capable of blocking the bitter taste associated with these sweetners. Senomyx is also looking to use its bitter-blocking technology in the pharmaceutical arena (1"The Tan Sheet" Jan. 16, 2006, p. 13)...
You may also be interested in...
Senomyx Seeks Alternatives To “Spoonful Of Sugar” To Make Meds Go Down
Senomyx expects to develop bitter flavor-blocking agents for use in pediatric OTC products in 2006, the biotechnology firm stated during a Jan. 12 presentation to investors
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.